AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The Company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute post-operative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers. 
Company Growth (employees)
Type
Public
HQ
Redwood City, US
Founded
2005
Size (employees)
39 (est)+9%
Website
acelrx.com
AcelRx Pharmaceuticals was founded in 2005 and is headquartered in Redwood City, US

AcelRx Pharmaceuticals Office Locations

AcelRx Pharmaceuticals has an office in Redwood City
Redwood City, US (HQ)
351 Galveston Dr

AcelRx Pharmaceuticals Data and Metrics

AcelRx Pharmaceuticals Financial Metrics

AcelRx Pharmaceuticals's revenue was reported to be $3.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

3.1 m

Gross profit (Q1, 2017)

(1 m)

Gross profit margin (Q1, 2017), %

(33%)

Net income (Q1, 2017)

(15.6 m)

EBIT (Q1, 2017)

(12.1 m)

Market capitalization (21-Jul-2017)

142.8 m

Cash (31-Mar-2017)

72.3 m
AcelRx Pharmaceuticals's current market capitalization is $142.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

29.5 m5.2 m19.3 m17.4 m

Revenue growth, %

(82%)269%(10%)

Cost of goods sold

1.8 m12.3 m

Gross profit

17.5 m5 m

Gross profit Margin, %

91%29%

R&D expense

21.4 m

General and administrative expense

15.6 m

Operating expense total

36.2 m42.9 m39.2 m49.3 m

EBIT

(6.7 m)(37.6 m)(20 m)(32 m)

EBIT margin, %

(23%)(722%)(104%)(184%)

Interest expense

1.5 m2.6 m3 m2.8 m

Pre tax profit

(33.4 m)(23.6 m)(43.2 m)

Income tax expense

760 k(34 k)

Net Income

(23.4 m)(33.4 m)(24.4 m)(43.2 m)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

15.4 m3 m4.5 m3.4 m3.1 m

Cost of goods sold

3.6 m3 m2.6 m4.1 m

Gross profit

(574 k)1.6 m787 k(1 m)

Gross profit Margin, %

(19%)34%23%(33%)

R&D expense

5.4 m4.2 m6.3 m4.6 m6.9 m

General and administrative expense

2.9 m3.8 m3.6 m4.1 m4.1 m

Operating expense total

8.3 m7.9 m9.9 m8.8 m11.1 m

EBIT

7.1 m(8.5 m)(8.3 m)(8 m)(12.1 m)

EBIT margin, %

46%(282%)(184%)(237%)(388%)

Interest expense

(713 k)(680 k)(687 k)(702 k)(774 k)

Pre tax profit

(11 m)(11.1 m)(15.6 m)

Income tax expense

(772 k)(2 k)

Net Income

5.1 m(11 m)(11.1 m)(11.4 m)(15.6 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

88.4 m60 m107.9 m80.3 m

Accounts Receivable

3.3 m5.8 m

Inventories

897 k948 k466 k2.2 m

Current Assets

104.6 m76.3 m118.9 m89.1 m

PP&E

5.2 m9.8 m8.6 m10.7 m

Total Assets

110 m86.4 m127.8 m100 m

Accounts Payable

2.3 m2.4 m1.6 m1.6 m

Total Debt

14.4 m24.9 m20.9 m18.6 m

Current Liabilities

6.9 m13.7 m12.8 m10.2 m

Total Liabilities

105.3 m

Additional Paid-in Capital

218.6 m225.4 m236.3 m241 m

Retained Earnings

(145.5 m)(178.8 m)(203.2 m)(246.4 m)

Total Equity

73.2 m46.7 m33.1 m(5.3 m)

Debt to Equity Ratio

0.2 x0.5 x0.6 x-3.5 x

Debt to Assets Ratio

0.1 x0.3 x0.2 x0.2 x

Financial Leverage

1.5 x1.9 x3.9 x-18.7 x
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

95 m105.4 m97.8 m92.5 m72.3 m

Accounts Receivable

17.4 m3.2 m4.2 m2 m2.7 m

Inventories

910 k1.3 m1.4 m1.9 m

Current Assets

122.6 m112.8 m105.6 m96.9 m78 m

PP&E

8.7 m8.2 m7.8 m8.8 m10.2 m

Total Assets

131.6 m121.2 m113.6 m106 m88.4 m

Accounts Payable

1.7 m3.6 m2.9 m1.4 m1.7 m

Current Liabilities

7.9 m16.8 m21 m15.5 m12.8 m

Additional Paid-in Capital

232.6 m237.6 m238.7 m239.9 m242.2 m

Retained Earnings

(192.7 m)(214.2 m)(225.3 m)(236.7 m)(261.9 m)

Total Equity

40 m23.4 m13.5 m3.3 m

Financial Leverage

3.3 x5.2 x8.4 x32.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(23.4 m)(33.4 m)(24.4 m)(43.2 m)

Depreciation and Amortization

593 k866 k2 m2.1 m

Accounts Receivable

(3.3 m)(2.5 m)

Inventories

(466 k)(1.7 m)

Accounts Payable

106 k90 k(786 k)(437 k)

Cash From Operating Activities

(487 k)(34.5 m)(20 m)(29.4 m)

Purchases of PP&E

(3.3 m)(5.5 m)(1.5 m)(3.7 m)

Cash From Investing Activities

(6.9 m)(5.8 m)8.2 m1.8 m

Cash From Financing Activities

47.9 m11.9 m59.6 m(26 k)

Interest Paid

1.1 m1.8 m2.1 m1.9 m
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

5.1 m(11 m)(11.1 m)(11.4 m)(15.6 m)

Accounts Receivable

17.4 m3.2 m4.2 m2 m2.7 m

Inventories

910 k1.3 m1.4 m1.9 m

Accounts Payable

2.8 m2.9 m1.6 m1.7 m3.6 m2.9 m1.4 m1.7 m
USDY, 2017

Revenue/Employee

79.7 k

AcelRx Pharmaceuticals Operating Metrics

FY, 2016

Phase III Trials

2

Patents (US)

20

Patents (foreign)

24

AcelRx Pharmaceuticals Market Value History

AcelRx Pharmaceuticals Online and Social Media Presence

AcelRx Pharmaceuticals News and Updates

AcelRx Pharmaceuticals Company Life and Culture

You may also be interested in